Report Overview

The US Hepatitis B therapeutics market is expected to grow at a CAGR of xx%, stood around at USD xx billion in 2019, and projected to reach USD xx billion by 2028 during the forecast period

Hepatitis B is a liver infection caused by the hepatitis B virus. Hepatitis B virus causes inflammation of the liver. In the US, an estimated 8,62,000 people were chronically infected in recent years. The rates of new Hepatitis B infection are highest among adults aged 40-49 years, reflecting low Hepatitis B vaccination coverage among adults at risk. The most common risk factor among people with new Hepatitis B infections is injecting drugs, related to the opioid crisis. A chronic Hepatitis B can cause severe implications like liver failure and liver cancer. The US government has made it mandatory for the people to go through the screening and monitoring since it's not easily recognizable. It is expected that many innovative therapies that have shown positive results in clinical trials will occupy the market in upcoming years



Market Growth Drivers

The key factors driving the market growth of the Hepatitis B market are increased cases of cirrhosis deaths, increasing population of old age, increased healthcare expenditure, and urbanization leading to better screening and treatment. Some of the trends and developments include government initiatives, public awareness, research, and developments in therapeutics. The growth of the market can be hindered by management challenges, lack of diagnostic facilities, high cost of medical care, legal regulations, and competition in the market